8-K

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, I2izl6U8QnYSidr+tn1qx0D6qMGsiijjgD/EDTK9B+JhCHSiqP/AMS0qUTBKYZTu 4qXJxQaLwXMO7RIpt+aUYA== 0000950103-05-000117.txt : 20050125 0000950103-05-000117.hdr.sgml : 20050125 20050125121559 ACCESSION NUMBER: 0000950103-05-000117 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20050125 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20050125 DATE AS OF CHANGE: 20050125 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SHIRE PHARMACEUTICALS GROUP PLC CENTRAL INDEX KEY: 0000936402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-29630 FILM NUMBER: 05546478 BUSINESS ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 BUSINESS PHONE: 1264333455 MAIL ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 8-K 1 jan2505_8k.htm 8-K


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 25, 2005

Shire Pharmaceuticals Group plc

(Exact name of registrant as specified in its charter)

England and Wales

(State or other jurisdiction of incorporation)

0-29630		98-0359573
(Commission File Number)		(IRS Employer Identification No.)

Hampshire International Business Park, Chineham, Basingstoke,
Hampshire, RG24 8EP England

(Address of principal executive offices)	(Zip code)

Registrant’s telephone number, including area code	44 1256 894 000

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events

Shire Pharmaceuticals Group plc has issued the press releases attached as Exhibits 99.01 and 99.02 which are incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

(c) Exhibits. The following exhibits are filed herewith:

99.01 Press Release dated January 25, 2005
99.02 Press Release dated January 25, 2005

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SHIRE PHARMACEUTICALS GROUP PLC

	By:	/s/ A C Russell

		Name: Angus Russell
		Title: Chief Financial Officer
Dated: January 25, 2005

EXHIBIT INDEX

Number		Description
99.01		Press Release dated January 25, 2005
99.02		Press Release dated January 25, 2005

EX-99.1 2 ex9901.htm EXHIBIT 99.1

Shire Pharmaceuticals Group plc Hampshire International Business Park, Chineham, Basingstoke RG24 8EP UK Tel +44 1256 894000 Fax +44 1256 894708 http://www.shire.com	EXHIBIT 99.01

25 January 2005

Shire Pharmaceuticals Group plc (the "Company")

Application has been made to the UK Listing Authority and the London Stock Exchange for a listing of 897,060 ordinary shares of 5p each in the Company to be admitted to the Official List.

These shares, ranking pari passu in all respects with the existing shares in issue, have been issued pursuant to the exchange of certain Exchangeable Shares in Shire Acquisition Inc., in accordance with the terms of the Merger Agreement with BioChem Pharma Inc.

T May
Company Secretary

For further information please contact:

Investor Relations

Cléa Rosenfeld +44 1256 894 160

Notes to editors

Shire Pharmaceuticals Group plc

Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing projects and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), and renal diseases. Shire has operations in the world’s key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.

For further information on Shire, please visit the Company’s website: www.shire.com.

GRAPHIC 3 logo.gif GRAPHIC begin 644 logo.gif M1TE&.#EA2@&=`/<```P(:"E(:+ MFX:+HX:+JH:+P(:5L8:5N8:>L8:>N8:GP)"5P)"5R)">N9">P)"GP)"GR)"P MUIN>HYN>JIN>N9N>P)NGL9NGN9NGR)NPR)NPSZ6>JJ6>L:6>R*6GN:6GP*6G MR*6GWJ6PR*6PSZ6PUJ6PWJ6ZWJ6Z[*7#WK"PL;"PN;"PP+"PWK"ZR+"ZS["Z MUK"ZWK"Z[+##S[##UK##WK##[+#,Y;JZP+JZR+JZS[JZUKJZWKK#WKK#[+K, MY;K,[+K5[,7#R,7#S\7#UL7#WL7#],7,R,7,S\7,UL7,Y<7,[,75Y<75[,7? M^\_,R,_,S\_,UL_,WL_,[,_5S\_5UL_5WL_5[,_?],_H^]K5UMK5WMK5Y=K5 M[-K?WMK?Y=K?]-KH^^3?[.3HWN3HY>3H[.3Q^^_H]._Q]._Z^_KQ]/KQ^_KZ M[/KZ^P`````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````/___R'Y!`$``/\`+`````!*`9T`0`C_`/\)'$BPH,&# M"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/`WF5ZC40F"R+3RH(`8E0UDF6 M,&/*G$FS)D)>+WNITL@HIBQ>`H?MDA7+IM&C2),J16@K%5"84"1H<#&0AP.J M$G_)2O7RWRU9O7`N'4NVK-FS!*-FB&(*%Q0M((?)NG5+X*RZ://JW7?2-+GJQQ&*FNJ68!\S778@7!=QR\D53AAT:7 M3__AW)6:LNO7L!F:/&FRM<1A6"0XB.)"0AN!9RX48&5QZ,]A`F_-BLV\^6M@ MHP3R`FH9(PL)DUAA(#%(0HN!GC*\_YC(:Y=`R,[3J^_;ZU8O6<@3`ILX0H*3 M$R=8A3:SOK___PO]A%$@!0PAD!NZH2%0,``VZ&!SMO`2WWS_R"4+A1$-0\8( M&>RP2B$92$#"$"-44,J#**;8EWL#O:?BBS#&*%TJ!+F$7"RV230+*0!"`L," M`0@@```&&%!``44VP("00PY@P`R&)%0&!@59%<&5$4``@0,I=$1&%PYH*29@ M(S`H(UIR"=0>+['$1Q$I.?Q`4F2>.%!``!NX\@\B0!H`P`$4+`2"D`,,```` M!!!90!X*Q1#``$Q""H`#9U8*T87K%1)!`0LHJ)"F`1Q@*`&%EEHJ`(8>>FB1 M`2P00R0.P?_PJ*%"JFI`JT>HH<81'00`@`"0,BE``!TH!$41J!8*[*$%")-0 M!\*:FNJA`2`)P)U=%#1%`;\FFV@!:QC$IP'*JEH`(982Y.9>"]Q:P$.KT.## MO/3.2\,;#.%RIP%#'BKJM50D)&NPRTZ:D"1!2BM``68>=&RRD*;:[+,0GTJ$ M0WJ$>JBP!U#KJZH`!""RR$4:>6<`.Z4+T2Q@#639G!V=<*B3>DK$10#D*@OL MM/WZBZJHD1IJ9+:-/BKLH90BA/#.I2[`4_<*8RRR7(B#MR$=F M(4F+0_1#!8[DDD$%JRS8R"87L5G2[?^89%[RX)LUVUTY/K1)';X@M`J'$A@X MT?$XP1?^_$O%,J=)19U(T@=X%(*7Z`@0I`P4S!(&%ITL?!%K[&3:7[ MX#]L44"*L*`%;I&`&7)1@?%<9!@:=*$0_V-BNX$$3D+HF0@+"O`'!@W!`=@; MHA1=$Z$*\6(^M\B?0YA0@3I,\8NOV<4OAF$+[E6H;6GPE0!8M0`:(&(.'BB9 MGYHTJFDQ"PH&641!!J:S825M(T1`EJ%.9:2G@1$MO%"%#+$UA[D0(/"/&K%D:!%H[PQHD&2)- M8#'I4(%*B">HP(4J^+0*5)C"(PPXG?]])!=H($(*3&`"'@SA#5%TB##`\`"2 MA4R.(Q/9D4Y0B(@$H@MF\((7NN`%-*#!BPBY11?0D(:VFM4,U3S((R!AUC"` MP:QCI6!"\$!6L[K5#$.UB"O6T`$@955DKMHD-&T!#*-"\[&0-2!J!&*2BNPB M%JRAB5P".)`D1O:+-!QC]P:R"V"L[2S?(^UD/_M9L4C'@[*+""!HPHO+(`/3F7^0PK$.(4,%Q@`3G/_`KGLTTNUCX]<5E]AH+W*)1>(L*(L:*A>T MJ;$M1F(KD#9(0#<2&`$N)`*,`F+JNNCE"!8J4``@.,$!&7#$/WJ@3<]5Y"4M MFV%Z#QF+Z,BD#2$B06(N8EJ%&'>_"&8((##`J($8P@45P$`+`J$1D]PE9=*1 M1>@2S&&$U,E].BB`=SQBDMQVN(6740@P/#B1$)R0!!)@A2`L,%^5A$%7-YBHZI?$!@I"*U(+&#!"@@`4_\8P<2.$'U,M3?UOQ"NCPF,^UN M3$:!I,+_Q`V9Q0]F*Q!5Z4C7JQZ(>NEID#@(($' M#.$!>)3WB7<1'UZ$9;KR>\A?!/&/,[1O((84^(D]>Q%:.&`':7#`$((1A1!D MA!?)E?@&Y8>I-%6D$5A`G\A7KAI22T05[V;YQ"ETEV#+_.8&__%O915X$1M4 M@$C!0F!@2D*1U$MF MD,`$1C^![X9W[557"/[,@@L'+*``/!!(+E:`,TNFR@`U0\@CA,"#'O3`Z$,@ MPA"$0&B$B-1K`(BH0+KP^EL1:60%F()#M+`%3BW@^J\OP`;&BY`71-WZ!<## M0/A@V%L%(*X(@8,'M`HV:A4``E!@I>_*[OV:2'"`\=POB".]9E-:"``"*4J"T"`U;8'`:``X`(2PA`'(#""JA*!BE()(14DWW0HRG<0B""'<\AW M4"-(\22!3R@M3B(##A$'CU(QA?(G37(`$6AY@!@`K1`^M?45:/_F$?H2)(+X M$/HB*O$D-&'8$!`P)/URB`50!0)C-)YG,$J3,$WC-._$ARQU+54X$+6D,X8R M4PHA#`NP3,(2`!AU2.4%%D*&%\/`,A^A`LO$`1*1"Q+@*Q5U4X;2*A"@`C$P MC1/P>G_24`4 M`X]($)[02_PB*<,"`R[4:!O1"KV",P6@`H:`CO_P"YJ0"?XU$,SG2SU3+M]T M*AUU+0M@!0TQ,-XT+'5H$%QS@XKB@X'T=3>5?&)8$!U@@Y(23.X3$7GP`$CB M2[;4AJD"*>ZB>8]&;*EWDPPA>#BYDSO_.12IY1)?P5T-T6?2$0N4YA&H,6IY MQI,-HA7O@1=".92G)A,B(4-J,F1,^2([5R$4MQ>7-3Q`A"/.E965\@LY,@PX M07\+D0E&T5AD62GO(3<&AVHH40$LL)09,8P>9`LL^)8J,I=!9I624491Z91L$,0H7-(FOZ2"I&9@'=Q%8$`)^ MD!!U(`&EX8,&=CN=4Y"ZN9L`4@L20EDP$7H2(`*.4`0.T`)S!A$6Q)6I\16: MZ9R,(P0.\%TN_S!GK*`;&&81BBD=@R>>?E,B6"`07%">,"8!6[!=E,59?0F? M`&*6-%$'I7$1XB9=!N:?X<,%ID=W+``3E_$56X>@?4,&Y?D;!?&>$+%B(=19 ME"FAKK$+Q,`23/!=;>`)66!"&&%!J8$IP/`5M>FA>E$,+$$(!1`%G_`"(V`( M(N``*7@:CPFCLP,%#F`&A&`*64`"X\4%.T`&$9HA"]0]T0FDZP%I&L$)@L`) MHZ5F9W`*)!`"/6J;7'D\3RJE#:*AYO80OA`"%?`/;5`!!O(##9:B>!$_J0%$ M(4>FSA$_&"*8#.$+)80##O`[W=,"1R($+$01HR8@,AID8(:GZO&4[^W1%4)F M$6/`(QF@>8Y0`?FI$9'HJ`ZBEQB:$"R``<3A`@X0"9Z`E1;!"_'V7%H1JI[: M%WI9$8X`80`(7(`$!)PC?-0+,VA`TM!JJ%9XP M:Q1`5%V-,6G^>A"!P`*'40:K4#T*>K(;,98;>[1],3P"T@LN-Q%F4`&^(1"E M<#T8L0N>,VE#H;61@1[[BA&EX`"=\`^0`%\9\`K!X`(%\&GOLQ5LZQIH&6RR M0`I!JV+)]@^X$&&9YBE_^S8+>Q[AF0LCX`!"$`BXT`(*`@Q/D`-DT+@J@YCO MX2:A2Q&FL`/B@2YO)J@7`0O7ZKEG(3SJ\A,N`:L%T0(6P*Z<8+K?A;JN:RG\ M:!&-H`,L4!\2P*[!(`08$`+SV;LP8D$4@I;2-J8/,0LCL`1N:0@%_X`"#8TP:`#%R<"$A![ MF%9".O!M[OL@;-(5P`!FM)L0DZL`4?`/>6L:&$&4_YL7;)(:P+`81DL0M."F M_Y`+/#`]#/S`,$(W,@28$E$*-U`!(:`#J_!`'APC(8<3&[K"],,RU!8?9(2P M,$P_`YQ?,]2?#V$+:MK!-YPB(NQ!I8"Q!E&X0>P@BLDR$R(+QE/`2:PR7$L2 MY3L1C*"F?1#%*6*3"O2P#C&,;K,*>=`%0Q`#2V4"+\`#;["=P6H[0124912M M;D,(5)`"=O)]6G4D1?(%B?`*8H@+A3`$$O_K=N,J%V%!(:/`PP_A!R'``DV+ M%D1@50BX*C6@!`V@BR`57("(3\#XXT,TP2`*)L$3UEB,&T M`/+*6F3DQ1CAPGD1#!OE,3,0"O\0R2>357^2`#EXC892`$3X#WI$$`/CAL=< M$4T0R38H)$5"CJ4)E*K1RDO1!G:R`$7P"J]0!=WX M>5J<%]QV)`\0!_L&)&2#C`K1!2+C,0`9`#%G$,>G+*U"$,)`"$D5`SU`!&CP M"%!L$,:0$920!VK_@`9X`,W_T`J$L`5$T`,Q0`-3@`:0T,PI8ADP#1MF8"<1 M@+J/L`')(CAM!!3D`38""R)PLP3F"JI!`!BX$B**"F*@GX" M`0E5A=@;,T(B%HH@A[`1H*`'18`"J0V3CST`'6,DW`B*J9*1!;$T M(V7BK7@U]ZWB&YY3#%$(!1"341@VAU4MOF2(L`@W"900$3P3K>``?H+>'A$* M7N"%HEW6UZ(&<3A2AN+D!'&'T1+.)VZ.5?Y2*V8.`#[@$&OPCMTX2#9UA/VB MZ,-"T*/3J:O'$EP`@+W8$%K>?EO]X`L!"@O`Y#EH3Z5XT*AX$.'8-/`\$"@^ MYG^XB>S8$)Y@+3AH`$9@!6+E!5;P!;7N!55@Z[7>!;[>!2D].WKYP@K_],@1 MP70ATU40T2YT='L!X-`+\0HFZ5%GB!#G?(KI7.K!I.:.6TV.H-00') M1>M(+,00*```(X`$2D3$&@``Z6"M&@@1,+0Q4T"[8*([7 MLN38?C"JJ-_<7M]^GN(O]4TR!2\)<]34?8D&D>8G8];5$M@;%`ONCA`;8`"D M@N40<>GE'I+!%#;F5]X!_Y*W,F#I+>K9?O`;D_#>3I#J2#9LKA`3X"=(?HT' M<"0;<'1$4%4!@.^&@N_7HNP;Q#*DD`K`H,@3@09!0MTYSQ`]L$YM>'D8^"^= MQR14SQ"#+23&G!"18.@(W^<@.3;?#NCY+>X/CT'18(/O`I!*J83;M7+>CS9E M("$'A15U@?$".I`#.1`$3T`';*D^45#D(`.*/6.#K!(`'H`&!%D0)_`Q%7TG MZ0P)7^YTIAU\7^XNIKT!3> EX-99.2 4 ex9902.htm EXHIBIT 99.2

Shire Pharmaceuticals Group plc Hampshire International Business Park, Chineham, Basingstoke RG24 8EP UK Tel +44 1256 894000 Fax +44 1256 894708 http://www.shire.com	EXHIBIT 99.02

25 January 2005

Shire Pharmaceuticals Group plc (the “Company”)

The Company announces that it was notified on 24 January 2005 under Sections 198 to 202 of the Companies Act that on 24 January 2005 Franklin Resources, Inc. and its affiliates had holdings managed on behalf of investment clients of 63,185,551 ordinary shares of £0.05p each in the capital of the Company. These holdings represent 12.948 per cent of the issued ordinary share capital of the Company.

T May
Company Secretary

For further information please contact:

Investor Relations

Cléa Rosenfeld	+	44 1256 894 160

Notes to editors

Shire Pharmaceuticals Group plc

Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing projects and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI) and renal diseases. Shire has operations in the world’s key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.

For further information on Shire, please visit the Company’s website: www.shire.com

-----END PRIVACY-ENHANCED MESSAGE-----